Enasidenib

1:42
AML: new targeted inhibitors as single agents?
Christoph Röllig
1:13
Enasidenib for IDH2-mutated MDS
Valeria Santini
1:27
Progress in AML & research at the University of Düsseldorf
Thomas Schröder
4:31
Personalized AML therapy with John Byrd: the beat AML trial and more
John Byrd
2:52
Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions
Eytan Stein
2:25
Beat AML: promising results with enasidenib for AML in the frontline
Eytan Stein
1:25
IDH inhibitors for AML: highlights from ASH 2018
Marina Konopleva
1:51
IDH1/2 inhibitors for upfront AML therapy and transfusion independence
Amir Fathi
4:42
Gene-based treatments show positive outcomes in AML
Harry Erba
4:06
Gene-targeting therapies for AML
Harry Erba
1:53
The promising role of IDH inhibitors in AML
Amir Fathi
3:29
Novel drugs and targets in MDS
Valeria Santini
2:13
A success story: IDH inhibitors for AML
Alexander Perl
3:51
Changes in the AML treatment landscape
Richard Stone
4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
1:32
IDH inhibitors for AML and MDS
Eunice Wang
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals